Matched cohort | |||||
---|---|---|---|---|---|
n-TPE (n = 33) | TPE (n = 39) | p | |||
Percentage of TG to target level in 2 daysa | 0.09% (1/11) | 68.75% (11/16) | 0.046 | ||
without fenofibrate | with fenofibrate | TPE without fenofibrate | TPE with fenofibrate | ||
0.09 (1/11) | 0 (0/5) | 68.75% (11/16) | 16.66% (2/12) | ||
P = 0.500b | P = 0.126b | ||||
Percentage of TG to targer level in 3 daysa | 44.44% (4/9) | 68.75% (11/16) | 0.912 | ||
without fenofibrate | with fenofibrate | TPE without fenofibrate | TPE with fenofibrate | ||
44.44% (4/9) | 17.64% (3/17) | 50.00% (8/16) | 13.33% (2/15) | ||
P = 0.151b | P = 0.032b | ||||
CTSI changes in 14 days | |||||
Improved | 61.54% (8/13) | 42.11% (8/19) | 0.288 | ||
Deteriorated | 38.46% (5/13) | 36.84% (7/19) | 0.927 | ||
Unchanged | 0 | 21.05% (4/19) | |||
Early recurrence (in 3 months) | 1 | 0 | |||
Local complicationsc | 31.25% (5/16) | 31.58% (6/19) | 0.984 | ||
Mortality | 0 | 0 |